The Cancer Anorexia/weight Loss Syndrome: Therapeutic Challenges

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2005 Jun 11

PMID 15946586

Citations 8

Authors

Karin F Giordano

Aminah Jatoi

Affiliations

Soon will be listed here.

Abstract

The cancer anorexia/weight loss syndrome is characterized by loss of weight, loss of appetite, overall decline in quality of life, and shortened survival in patients with advanced incurable cancer. It is highly prevalent. To date, treatment options that have been firmly established with good scientific evidence are limited to progestational agents and corticosteroids, both of which have been demonstrated to improve appetite but have otherwise failed to have a favorable impact on some of the other aspects of this syndrome. As the mechanisms behind this syndrome are further elucidated, more effective therapeutic strategies will likely emerge.

Citing Articles

Cell-death induced immune response and coagulopathy promote cachexia in .

Singh A, Hu Y, Lopes R, Lane L, Woldemichael H, Xu C bioRxiv. 2025; .

PMID: 39829769 PMC: 11741341. DOI: 10.1101/2025.01.07.631515.

A Randomized Clinical Trial Investigating an Integrated Nursing Educational Program to Mitigate Chemotherapy-Induced Nausea and Vomiting in Cancer Patients: The NIV-EC Trial.

Mazzega-Fabbro C, Polesel J, Brusutti L, Malnis E, Sirelli C, Drigo A Cancers (Basel). 2023; 15(21).

PMID: 37958348 PMC: 10649710. DOI: 10.3390/cancers15215174.

Cancer cachexia: lessons from Drosophila.

Liu Y, Saavedra P, Perrimon N Dis Model Mech. 2022; 15(3).

PMID: 35319749 PMC: 8961677. DOI: 10.1242/dmm.049298.

Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.

Advani S, Advani P, VonVille H, Jafri S BMC Cancer. 2018; 18(1):1174.

PMID: 30482179 PMC: 6260745. DOI: 10.1186/s12885-018-5080-4.

Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial.

Mehrzad V, Afshar R, Akbari M Adv Biomed Res. 2016; 5:60.

PMID: 27135029 PMC: 4832883. DOI: 10.4103/2277-9175.179182.

References

Loprinzi C, Bernath A, Schaid D, Malliard J, Athmann L, Michalak J . Phase III evaluation of 4 doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Oncology. 1994; 51 Suppl 1:2-7. DOI: 10.1159/000227407. View

Loprinzi C, Laurie J, Wieand H, Krook J, Novotny P, Kugler J . Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol. 1994; 12(3):601-7. DOI: 10.1200/JCO.1994.12.3.601. View

DeWys W, Begg C, Lavin P, Band P, Bennett J, Bertino J . Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980; 69(4):491-7. DOI: 10.1016/s0149-2918(05)80001-3. View

Loprinzi C, Goldberg R, Su J, Mailliard J, Kuross S, Maksymiuk A . Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol. 1994; 12(6):1126-9. DOI: 10.1200/JCO.1994.12.6.1126. View

Walsh D, Rybicki L, Nelson K, Donnelly S . Symptoms and prognosis in advanced cancer. Support Care Cancer. 2002; 10(5):385-8. DOI: 10.1007/s00520-001-0318-z. View

Sarhill N, Mahmoud F, Walsh D, Nelson K, Komurcu S, Davis M . Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003; 11(10):652-9. DOI: 10.1007/s00520-003-0486-0. View

Finkelstein D, Cassileth B, Bonomi P, Ruckdeschel J, Ezdinli E, Wolter J . A pilot study of the Functional Living Index-Cancer (FLIC) Scale for the assessment of quality of life for metastatic lung cancer patients. An Eastern Cooperative Oncology Group study. Am J Clin Oncol. 1988; 11(6):630-3. DOI: 10.1097/00000421-198812000-00007. View

Socinski M, Zhang C, Herndon 2nd J, Dillman R, Clamon G, Vokes E . Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol. 2004; 15(7):1033-41. DOI: 10.1093/annonc/mdh282. View

Jatoi A, Rowland K, Loprinzi C, Sloan J, Dakhil S, MacDonald N . An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004; 22(12):2469-76. DOI: 10.1200/JCO.2004.06.024. View

10.

Ravasco P, Monteiro-Grillo I, Vidal P, Camilo M . Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol. 2005; 23(7):1431-8. DOI: 10.1200/JCO.2005.02.054. View

11.

Torelli G, Meguid M, Moldawer L, Edwards 3rd C, Kim H, Carter J . Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol. 1999; 277(3):R850-5. DOI: 10.1152/ajpregu.1999.277.3.R850. View

12.

Kardinal C, Loprinzi C, Schaid D, HASS A, Dose A, Athmann L . A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990; 65(12):2657-62. DOI: 10.1002/1097-0142(19900615)65:12<2657::aid-cncr2820651210>3.0.co;2-s. View

13.

Loprinzi C, Kugler J, Sloan J, Mailliard J, Krook J, Wilwerding M . Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999; 17(10):3299-306. DOI: 10.1200/JCO.1999.17.10.3299. View

14.

Jatoi A, Kumar S, Sloan J, Nguyen P . On appetite and its loss. J Clin Oncol. 2000; 18(15):2930-2. DOI: 10.1200/JCO.2000.18.15.2930. View

15.

Llovera M, Lopez-Soriano J, Carbo N, Agell N, Lopez-Soriano F, Argiles J . Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998; 142(1-2):183-9. DOI: 10.1016/s0303-7207(98)00105-1. View

16.

MOERTEL C, SCHUTT A, Reitemeier R, Hahn R . Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer. 1974; 33(6):1607-9. DOI: 10.1002/1097-0142(197406)33:6<1607::aid-cncr2820330620>3.0.co;2-v. View

17.

Kotler D, Tierney A, Wang J, Pierson Jr R . Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr. 1989; 50(3):444-7. DOI: 10.1093/ajcn/50.3.444. View

18.

Baracos V, DEVIVO C, Hoyle D, GOLDBERG A . Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol. 1995; 268(5 Pt 1):E996-1006. DOI: 10.1152/ajpendo.1995.268.5.E996. View

19.

Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M . Characterization of a cancer cachectic factor. Nature. 1996; 379(6567):739-42. DOI: 10.1038/379739a0. View

20.

Ovesen L, Allingstrup L, Hannibal J, Mortensen E, Hansen O . Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J Clin Oncol. 1993; 11(10):2043-9. DOI: 10.1200/JCO.1993.11.10.2043. View